Does Vitamin D Supplementation Slow Brain Volume Loss in Multiple Sclerosis? A 4-Year Observational Study.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of multiple sclerosis, published as an observational study.

Methods: A 4-year observational, non-interventional study design was applied to evaluate the association between vitamin D supplementation and disease progression.

Why It Was Studied

Background and Aims: Vitamin D is currently well regarded for its pleiotropic effects on the immune system, stimulating an anti-inflammatory response and enhancing immune tolerance.

Vitamin D deficiency is an established risk factor for multiple sclerosis (MS).

Who Took Part

The abstract describes 97 subjects taking part.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Altogether, 132 relapsing-remitting multiple sclerosis patients were enrolled in the study (97 subjects in the group with vitamin D supplementation and 35 subjects in the group without supplementation).

How the Study Was Run

The researchers set it up as a randomized study.

The subjects were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

What Was Measured

Most studies have evaluated the effect of vitamin D supplementation on clinical and radiological activity, yet very few have examined the impact on brain atrophy.

The subject headings attached to it are Vitamin D, Brain, Dietary Supplements, Disease Progression, Atrophy, Magnetic Resonance Imaging and Multiple Sclerosis, Relapsing-Remitting.

Author keywords: supplementation.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 97 subjects in people with multiple sclerosis.

The publication is from 2025 (Nutrients), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Multiple sclerosis research.